The fight against COVID19
23.40k followers • 14 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
Performance
| Watchlist | Change today | 1-month return | 1-year return | Total return |
|---|---|---|---|---|
| The fight against COVID19 | +1.08% | - | - | - |
| ^GSPC | +3.06% | -1.68% | -8.62% | +4106.17% |
14 symbols
| Symbol | Company name | Last price | Change | % change | Market time | Volume | Avg vol (3-month) | Market cap |
|---|---|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 182.29 | +2.63 | +1.46% | 4:00 pm GMT-4 | 9.37M | 7.54M | 479.68B |
| PFE | Pfizer Inc. | 51.59 | +1.50 | +2.99% | 4:05 pm GMT-4 | 15.70M | 24.90M | 289.47B |
| ABBV | AbbVie Inc. | 152.34 | +2.89 | +1.93% | 4:03 pm GMT-4 | 7.90M | 7.28M | 269.20B |
| SNY | Sanofi | 53.42 | +3.00 | +5.95% | 4:00 pm GMT-4 | 4.59M | 2.33M | 133.41B |
| GSK | GSK plc | 43.69 | +0.94 | +2.20% | 4:00 pm GMT-4 | 3.93M | 5.75M | 111.06B |
| GILD | Gilead Sciences, Inc. | 63.08 | +0.50 | +0.80% | 4:00 pm GMT-4 | 9.15M | 8.29M | 79.12B |
| REGN | Regeneron Pharmaceuticals, Inc. | 612.49 | +5.10 | +0.84% | 4:00 pm GMT-4 | 815.43k | 706.23k | 67.28B |
| MRNA | Moderna, Inc. | 144.27 | +1.01 | +0.71% | 4:00 pm GMT-4 | 8.45M | 6.10M | 57.38B |
| TAK | Takeda Pharmaceutical Company Limited | 13.84 | +0.11 | +0.80% | 4:00 pm GMT-4 | 2.99M | 2.69M | 42.98B |
| BNTX | BioNTech SE | 134.04 | +1.75 | +1.32% | 4:00 pm GMT-4 | 1.02M | 1.40M | 32.57B |
| NVAX | Novavax, Inc. | 51.67 | -0.14 | -0.27% | 4:00 pm GMT-4 | 4.83M | 5.99M | 4.04B |
| VIR | Vir Biotechnology, Inc. | 24.84 | -1.05 | -4.06% | 4:00 pm GMT-4 | 2.85M | 1.61M | 3.29B |
| INO | Inovio Pharmaceuticals, Inc. | 1.94 | -0.07 | -3.48% | 4:00 pm GMT-4 | 8.87M | 6.17M | 444.34M |
- Zacks
Regeneron (REGN) Gains But Lags Market: What You Should Know
Regeneron (REGN) closed at $612.49 in the latest trading session, marking a +0.84% move from the prior day.
- Reuters
BioNTtech in conflict with regulator over new COVID vaccine approval - WAS
The launch of German drugmaker BioNTech's vaccine adapted to the Omicron coronavirus variant may be delayed due to a disagreement with the regulator over the approval process, the Welt Am Sonntag (WAS) newspaper reported on Saturday. The regulator should still decide by the end of June whether or not to approve the new vaccine but BioNTech Chief Executive Ugur Sahin does not plan to submit any new clinical trials, WAS reported, citing the Financial Times. The reason for this was that the approval "should go through the same regulatory process as ordinary flu vaccines", which would allow the new COVID-19 vaccine to be delivered in three months, WAS cited Sahin as saying.
- Zacks
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Novavax (NVAX) closed at $51.67, marking a -0.27% move from the previous day.
